相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer
Chris Twelves et al.
CLINICAL BREAST CANCER (2010)
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Third consensus on medical treatment of metastatic breast cancer
S. Beslija et al.
ANNALS OF ONCOLOGY (2009)
The Halichondrins and E7389
Katrina L. Jackson et al.
CHEMICAL REVIEWS (2009)
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Alvaro Moreno-Aspitia et al.
MAYO CLINIC PROCEEDINGS (2009)
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
Armelle Dufresne et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin
Donnette A. Dabydeen et al.
MOLECULAR PHARMACOLOGY (2006)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
G Kuznetsov et al.
CANCER RESEARCH (2004)
Structurally simplified macrolactone analogues of halichondrin B
BM Seletsky et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
分享论文
